USP54 and neoplasm: Subcutaneous xenograft growth and tail vein injection experiments validated these findings <i>in vivo</i>.<h4>Conclusions</h4>Our comprehensive multi-omics analysis and experimental validation identify the deubiquitinase USP54 as a novel promoter of PDAC progression within a spatially organized tumor-immune microenvironment.